Should You Scoop Up Shares of This Promising Biotech on the Dip?

The group of technologies that enable gene editing help scientists modify an organism's DNA. This field is very promising since it could help unlock successful and innovative therapies for various illnesses, including those with few (if any) current treatment options. That's why biotech investors would do well to pay attention to companies that focus on gene editing.

Investing in the right one could turn out to bring rich returns down the road. Let's look at one of the more prominent pure-play gene-editing stocks on the market: Editas Medicine (NASDAQ: EDIT). This company recently took a nosedive following a disappointing clinical update. Is now a good time to purchase its shares?